Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours.

Huang M, Yang W, Zhu J, Mariño-Enríquez A, Zhu C, Chen J, Wu Y, Quan Y, Qiu H, Li X, Chai L, Fletcher JA, Ou WB.

Br J Cancer. 2019 Nov 28. doi: 10.1038/s41416-019-0657-5. [Epub ahead of print]

PMID:
31776458
2.

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor.

Serrano C, Fletcher JA.

Oncotarget. 2019 Oct 29;10(59):6286-6287. doi: 10.18632/oncotarget.27277. eCollection 2019 Oct 29. No abstract available.

3.

Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors.

Pang Y, Xie F, Cao H, Wang C, Zhu M, Liu X, Lu X, Huang T, Shen Y, Li K, Jia X, Li Z, Zheng X, Wang S, He Y, Wang L, Fletcher JA, Wang Y.

Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22746-22753. doi: 10.1073/pnas.1914542116. Epub 2019 Oct 21.

PMID:
31636198
4.

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.

Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S.

Clin Cancer Res. 2019 Aug 30. doi: 10.1158/1078-0432.CCR-19-2150. [Epub ahead of print]

PMID:
31471313
5.

Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.

Ou WB, Ni N, Zuo R, Zhuang W, Zhu M, Kyriazoglou A, Wu D, Eilers G, Demetri GD, Qiu H, Li B, Marino-Enriquez A, Fletcher JA.

Oncogene. 2019 Sep;38(39):6615-6629. doi: 10.1038/s41388-019-0894-3. Epub 2019 Aug 1.

PMID:
31371779
6.

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.

Hsueh YS, Chang HH, Shan YS, Sun HS, Fletcher JA, Li CF, Chen LT.

Oncogene. 2019 Sep;38(38):6550-6565. doi: 10.1038/s41388-019-0900-9. Epub 2019 Jul 30.

7.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.

Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S.

Mol Cancer Ther. 2019 Nov;18(11):1985-1996. doi: 10.1158/1535-7163.MCT-18-1224. Epub 2019 Jul 15.

PMID:
31308077
8.

Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map.

Yen CC, Chen LT, Li CF, Chen SC, Chua WY, Lin YC, Yen CH, Chen YC, Yang MH, Chao Y, Fletcher JA.

Int J Oncol. 2019 Aug;55(2):536-546. doi: 10.3892/ijo.2019.4829. Epub 2019 Jun 21.

PMID:
31268158
9.

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Jul;121(3):281. doi: 10.1038/s41416-019-0487-5.

10.

Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.

Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, Marvin DL, Ligorio M, Dershowitz L, McCarthy KM, Karabacak MN, Fletcher JA, Sgroi DC, Iafrate JA, Maheswaran S, Dyson NJ, Haber DA, Rawls JF, Langenau DM.

Cell. 2019 Jun 13;177(7):1903-1914.e14. doi: 10.1016/j.cell.2019.04.004. Epub 2019 Apr 25.

PMID:
31031007
11.

Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver.

Fletcher JA, Deja S, Satapati S, Fu X, Burgess SC, Browning JD.

JCI Insight. 2019 Apr 23;5. pii: 127737. doi: 10.1172/jci.insight.127737.

12.

Pyruvate-Carboxylase-Mediated Anaplerosis Promotes Antioxidant Capacity by Sustaining TCA Cycle and Redox Metabolism in Liver.

Cappel DA, Deja S, Duarte JAG, Kucejova B, Iñigo M, Fletcher JA, Fu X, Berglund ED, Liu T, Elmquist JK, Hammer S, Mishra P, Browning JD, Burgess SC.

Cell Metab. 2019 Jun 4;29(6):1291-1305.e8. doi: 10.1016/j.cmet.2019.03.014. Epub 2019 Apr 18.

PMID:
31006591
13.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

14.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Mar;120(6):612-620. doi: 10.1038/s41416-019-0389-6. Epub 2019 Feb 22. Erratum in: Br J Cancer. 2019 May 23;:.

PMID:
30792533
15.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

16.

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.

Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC.

Oncogene. 2019 Feb;38(8):1200-1210. doi: 10.1038/s41388-018-0508-5. Epub 2018 Sep 21.

17.

ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia.

Cao M, Carrasco RD, Dubuc AM, Dal Cin P, Fletcher JA, Xiao S.

Leuk Lymphoma. 2019 Feb;60(2):556-558. doi: 10.1080/10428194.2018.1493733. Epub 2018 Aug 30. No abstract available.

PMID:
30160587
18.

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.

Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT.

Cancer Sci. 2018 Nov;109(11):3591-3601. doi: 10.1111/cas.13773. Epub 2018 Sep 21.

19.

Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.

Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5746-E5755. doi: 10.1073/pnas.1802079115. Epub 2018 Jun 4.

20.

Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.

Schaefer IM, Fletcher JA, Nielsen GP, Shih AR, Ferrone ML, Hornick JL, Qian X.

Cancer Cytopathol. 2018 Aug;126(8):552-566. doi: 10.1002/cncy.22000. Epub 2018 May 14.

21.

Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice.

Fletcher JA, Linden MA, Sheldon RD, Meers GM, Morris EM, Butterfield A, Perfield JW 2nd, Rector RS, Thyfault JP.

Exp Physiol. 2018 Mar 1;103(3):408-418. doi: 10.1113/EP086629. Epub 2018 Jan 16.

22.

BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas.

Mariño-Enriquez A, Lauria A, Przybyl J, Ng TL, Kowalewska M, Debiec-Rychter M, Ganesan R, Sumathi V, George S, McCluggage WG, Nucci MR, Lee CH, Fletcher JA.

Am J Surg Pathol. 2018 Mar;42(3):335-341. doi: 10.1097/PAS.0000000000000993.

PMID:
29200103
23.

Anti-inflammatory effects of exercise training in adipose tissue do not require FGF21.

Porter JW, Rowles JL 3rd, Fletcher JA, Zidon TM, Winn NC, McCabe LT, Park YM, Perfield JW 2nd, Thyfault JP, Rector RS, Padilla J, Vieira-Potter VJ.

J Endocrinol. 2017 Nov;235(2):97-109. doi: 10.1530/JOE-17-0190. Epub 2017 Aug 1.

24.

Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.

Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB.

Cancer Res. 2017 Sep 15;77(18):5107-5117. doi: 10.1158/0008-5472.CAN-17-0917. Epub 2017 Jul 31.

25.

What is New in Gastrointestinal Stromal Tumor?

Schaefer IM, Mariño-Enríquez A, Fletcher JA.

Adv Anat Pathol. 2017 Sep;24(5):259-267. doi: 10.1097/PAP.0000000000000158. Review.

26.

Aerobic capacity mediates susceptibility for the transition from steatosis to steatohepatitis.

Morris EM, McCoin CS, Allen JA, Gastecki ML, Koch LG, Britton SL, Fletcher JA, Fu X, Ding WX, Burgess SC, Rector RS, Thyfault JP.

J Physiol. 2017 Jul 15;595(14):4909-4926. doi: 10.1113/JP274281. Epub 2017 Jun 27.

27.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

28.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH.

JAMA Oncol. 2017 Jul 1;3(7):944-952. doi: 10.1001/jamaoncol.2016.6728. Erratum in: JAMA Oncol. 2017 Jul 1;3(7):1002.

29.

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors.

Obata Y, Horikawa K, Takahashi T, Akieda Y, Tsujimoto M, Fletcher JA, Esumi H, Nishida T, Abe R.

Oncogene. 2017 Jun 29;36(26):3661-3672. doi: 10.1038/onc.2016.519. Epub 2017 Feb 13.

30.

ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.

Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL, Fletcher JA.

J Pathol. 2017 Feb;241(3):316-323. doi: 10.1002/path.4836. Epub 2016 Dec 15. Review. Erratum in: J Pathol. 2017 Jun;242(2):260.

31.

KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions.

Fletcher JA.

Cancer Res. 2016 Nov 1;76(21):6140-6142. No abstract available.

32.

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.

Ou WB, Lu M, Eilers G, Li H, Ding J, Meng X, Wu Y, He Q, Sheng Q, Zhou HM, Fletcher JA.

Br J Cancer. 2016 Nov 8;115(10):1253-1263. doi: 10.1038/bjc.2016.331. Epub 2016 Oct 13.

33.

Targeting SALL4 by entinostat in lung cancer.

Yong KJ, Li A, Ou WB, Hong CK, Zhao W, Wang F, Tatetsu H, Yan B, Qi L, Fletcher JA, Yang H, Soo R, Tenen DG, Chai L.

Oncotarget. 2016 Nov 15;7(46):75425-75440. doi: 10.18632/oncotarget.12251.

34.

Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.

de Jong Y, van Maldegem AM, Marino-Enriquez A, de Jong D, Suijker J, Briaire-de Bruijn IH, Kruisselbrink AB, Cleton-Jansen AM, Szuhai K, Gelderblom H, Fletcher JA, Bovée JV.

Lab Invest. 2016 Oct;96(10):1128-37. doi: 10.1038/labinvest.2016.91. Epub 2016 Sep 12.

35.

Aerobic capacity and hepatic mitochondrial lipid oxidation alters susceptibility for chronic high-fat diet-induced hepatic steatosis.

Morris EM, Meers GM, Koch LG, Britton SL, Fletcher JA, Fu X, Shankar K, Burgess SC, Ibdah JA, Rector RS, Thyfault JP.

Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E749-E760. doi: 10.1152/ajpendo.00178.2016. Epub 2016 Sep 6.

36.

A return to ad libitum feeding following caloric restriction promotes hepatic steatosis in hyperphagic OLETF rats.

Linden MA, Fletcher JA, Meers GM, Thyfault JP, Laughlin MH, Rector RS.

Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G387-95. doi: 10.1152/ajpgi.00089.2016. Epub 2016 Jul 21.

37.

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.

38.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

39.

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.

Falkenhorst J, Grunewald S, Mühlenberg T, Marino-Enriquez A, Reis AC, Corless C, Heinrich M, Treckmann J, Podleska LE, Schuler M, Fletcher JA, Bauer S.

Oncotarget. 2016 Jul 5;7(27):41390-41403. doi: 10.18632/oncotarget.9159.

40.

Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.

de Graaff MA, de Rooij MA, van den Akker BE, Gelderblom H, Chibon F, Coindre JM, Marino-Enriquez A, Fletcher JA, Cleton-Jansen AM, Bovée JV.

Br J Cancer. 2016 May 24;114(11):1219-26. doi: 10.1038/bjc.2016.117. Epub 2016 May 3.

41.

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.

Yang P, Chen W, Li X, Eilers G, He Q, Liu L, Wu Y, Wu Y, Yu W, Fletcher JA, Ou WB.

Oncotarget. 2016 May 31;7(22):32652-63. doi: 10.18632/oncotarget.8999.

42.

Reporting of Diagnostic Cytogenetic Results.

Giersch ABS, Bieber FR, Dubuc AM, Fletcher JA, Ligon AH, Mason-Suares H, Morton CC, Weremowicz S, Xiao S, Cin PD.

Curr Protoc Hum Genet. 2016 Apr 1;89:A.1D.1-A.1D.23. doi: 10.1002/0471142905.hg01ds89.

PMID:
27037490
43.

Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver.

Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC.

J Clin Invest. 2016 Apr 1;126(4):1605. doi: 10.1172/JCI86695. Epub 2016 Apr 1. No abstract available.

44.

Fibroblast growth factor 21 and exercise-induced hepatic mitochondrial adaptations.

Fletcher JA, Linden MA, Sheldon RD, Meers GM, Morris EM, Butterfield A, Perfield JW 2nd, Thyfault JP, Rector RS.

Am J Physiol Gastrointest Liver Physiol. 2016 May 15;310(10):G832-43. doi: 10.1152/ajpgi.00355.2015. Epub 2016 Mar 24.

45.

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.

Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, Demetri GD, Wagner AJ.

Oncotarget. 2016 Mar 29;7(13):16581-92. doi: 10.18632/oncotarget.7667.

46.

ALK-rearranged renal cell carcinomas in children.

Cajaiba MM, Jennings LJ, Rohan SM, Perez-Atayde AR, Marino-Enriquez A, Fletcher JA, Geller JI, Leuer KM, Bridge JA, Perlman EJ.

Genes Chromosomes Cancer. 2016 May;55(5):442-51. doi: 10.1002/gcc.22346. Epub 2016 Feb 23.

PMID:
26773439
47.

Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver.

Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston KA, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, Burgess SC.

J Clin Invest. 2015 Dec;125(12):4447-62. doi: 10.1172/JCI82204. Epub 2015 Nov 16. Erratum in: J Clin Invest. 2016 Apr 1;126(4):1605. Livingston, Kenneth [corrected to Livingston, Kenneth A].

48.

Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.

De Rienzo A, Archer MA, Yeap BY, Dao N, Sciaranghella D, Sideris AC, Zheng Y, Holman AG, Wang YE, Dal Cin PS, Fletcher JA, Rubio R, Croft L, Quackenbush J, Sugarbaker PE, Munir KJ, Battilana JR, Gustafson CE, Chirieac LR, Ching SM, Wong J, Tay LC, Rudd S, Hercus R, Sugarbaker DJ, Richards WG, Bueno R.

Cancer Res. 2016 Jan 15;76(2):319-28. doi: 10.1158/0008-5472.CAN-15-0751. Epub 2015 Nov 10.

49.

Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats.

Linden MA, Lopez KT, Fletcher JA, Morris EM, Meers GM, Siddique S, Laughlin MH, Sowers JR, Thyfault JP, Ibdah JA, Rector RS.

Appl Physiol Nutr Metab. 2015 Oct;40(10):1038-47. doi: 10.1139/apnm-2015-0236. Epub 2015 Jun 24.

50.

Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma.

Wong WJ, Lauria A, Hornick JL, Xiao S, Fletcher JA, Marino-Enriquez A.

Genes Chromosomes Cancer. 2016 Jan;55(1):25-9. doi: 10.1002/gcc.22295. Epub 2015 Sep 10.

Supplemental Content

Loading ...
Support Center